Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Latest action · Jul 20, 2017 Referred to the House Committee on Energy and Commerce.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJul 20, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
This bill amends the Federal Food, Drug, and Cosmetic Act to include Middle East respiratory syndrome under the priority review voucher program for tropical diseases, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)Cosponsors 5
Members who signed on, in the order they did. Signatures ran from Jul 20, 2017 to Jul 18, 2018; 3 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-PA | Brendan F. Boyle | Original | Jul 20, 2017 |
| R-PA | Keith J. Rothfus | Original | Jul 20, 2017 |
| R-KS | Roger Marshall | Original | Jul 20, 2017 |
| D-MD | John K. Delaney | Jun 5, 2018 | |
| R-NE | Jeff Fortenberry | Jul 18, 2018 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jul 20, 2017 |
Actions 2
Everything that happened, newest first.
- Jul 20, 2017Introduced in House
- Jul 20, 2017Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 123, July 20, 2017, page H6147.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 6033 | Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act | Reintroduction of | Sep 14, 2016 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.
- Short Titles as Introduced
- Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Jul 20, 2017Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
